Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of [212Pb]VMT-Alpha-NET in SSTR-Positive Cancers
NCT06479811Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2025
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Phase 1, open-label trial of VMT-α-NET in gastrointestinal neuroendocrine tumor, pheochromocytoma, Paraganglioma (PGL) and 3 more (3 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose and Safety of [212Pb]VMT-alpha-NET at MTD up to 6 years. Started Aug 2025; status: recruiting.
02
Drugs
VMT-α-NET
03
Conditions
gastrointestinal neuroendocrine tumorpheochromocytomaParaganglioma (PGL)small cell lung cancer (SCLC)kidney cancer
Beyond the preview
Go deeper on NCT06479811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06479811.